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Low Serum Bilirubin Level as an Independent Predictor of
Stroke Incidence
A Prospective Study in Korean Men and Women
Heejin Kimm, MD, PhD; Ji Eun Yun, PhD; Jaeseong Jo, BS; Sun Ha Jee, PhD
Background and Purpose—Bilirubin is not only a waste end-product but also an antioxidant. Bilirubin is known to be
associated with decrease in cardiovascular risk in men, but its relationship to stroke was not clearly understood.
Methods—Serum bilirubin concentrations were measured in 78 724 health examinees (41 054 men, aged 30–89 years)
from 1994 to 2001. The subjects with potential hepatobiliary diseases or Gilbert syndrome were excluded from analysis.
Stroke incidence outcome was collected from hospital records of admission attributable to stroke from 1994 to 2007.
Results—Serum bilirubin measurements were divided into 4 levels: 0 to 10.2, 10.3 to 15.3, 15.4 to 22.1, and 22.2 to
34.2 mol/L. The number of stroke cases was 1137 in men and 827 in women. In Cox proportional hazard models,
participants with a higher level of bilirubin showed lower hazard ratios in men with ischemic stroke after adjustment
for multiple confounding factors compared to the lowest level of bilirubin (hazard ratio [HR], 0.72; 95% CI, 0.58–0.90
in level 3; HR, 0.66; 95% CI, 0.49–0.89 in level 4; P for trend0.016). The risk of all stroke types also decreased as
bilirubin levels increased (HR, 0.81; 95% CI, 0.68–0.97 in level 3; HR, 0.74; 95% CI, 0.58–0.94 in level 4; P for
trend0.0071). However, these associations were not seen in hemorrhagic stroke or in women.
Conclusions—These findings suggest that serum bilirubin might have some protective function against stroke risk
in men. (Stroke. 2009;40:3422-3427.)
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As stroke is becoming more prevalent in both developedand developing countries, the prevention of stroke is
becoming crucial.1 In Korea, stroke is the second leading
cause of death after cancer.2
It has been suggested that bilirubin is not only a waste
end-product but also an antioxidant3–5 that may protect
against diseases associated with oxidative stress.6 In several
prospective studies, an inverse relationship has been reported
between bilirubin and the following diseases: cardiovascular
disease (CVD),7,8 coronary heart disease,9 myocardial infarc-
tion,10 ischemic heart disease,11 and all-cause and cancer
mortality in men,12 although some of them failed to reach
statistical significance in CVD.12 Cross-sectional studies
reported similar results with coronary artery disease,13,14
peripheral vascular disease,15,16 carotid intimal-medial thick-
ness,17,18 and stroke.19 This inverse relationship of bilirubin to
CVD was confirmed by meta-analysis,20 and bilirubin has
been discussed as a therapeutic target for CVD.5,6
In a recent cross-sectional study, it was shown that total
bilirubin and stroke prevalence have an inverse association in
the representative national data in which higher bilirubin
level was not only associated with reduced stroke prevalence
but also associated with favorable stroke outcomes.19 How-
ever, the relationship between bilirubin and stroke has not
been fully understood because of limited reports on this issue.
Information such as subtypes of stroke or various ethnic
groups is also limited.
Therefore, we analyzed the association between serum
bilirubin levels and incidences of ischemic, hemorrhagic, and
all stroke types in a large prospective cohort study in Korea.
Materials and Methods
Study Population
The initial study population consisted of 122 769 participants who
underwent health examinations at 2 health examination centers in
Seoul from 1994 to 2001. Among the initial subjects, subjects with
missing data in the major variables (n15 503), hemoglobin level
10 g/dL or 20 g/dL (n1318), past history of CVD, cerebrovas-
cular accident, cancer, history of kidney disease or serum creatinine
2.0 mg/dL, or past history of admission (n10 928) were ex-
cluded. Among the 95 220 (53 217 men) participants, potential
Gilbert syndrome group (total bilirubin 34.2 mol/L [2.0 mg/dL],
aspartate aminotransferase 80 IU/L, alanine transaminase 80
IU/L, gamma glutamyl transpeptidase [GGT] 80 IU/L, and no
self-reported history of hepatobiliary disease; n662) and potential
hepatobiliary disease group (total bilirubin 34.2 mol/L or aspar-
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tate aminotransferase 80 IU/L or aspartate aminotransferase 80
IU/L or serum albumin3.5 g/dL or positive self-reported history of
hepatobiliary disease; n15 834) were also excluded to avoid
confounding factors. The definition of the potential Gilbert syn-
drome group was modified from previous works.21 The potential
hepatobiliary disease group was defined according to the US
NHANES study.19 Finally, 78 724 health examinees (41 054 men,
aged 30–89 years) were selected for the analyses. Consent from each
examinee was not specially obtained because the data were collected
from routine health examinations. The study was approved by the
Institutional review board of human research of Yonsei University.
Data Collection
Baseline information was obtained from the health examinations
from 1994 to 2001. Each participant completed systemized question-
naires that include smoking habit (never smoker, ex-smoker, or
current smoker), alcohol habit (nondrinker or drinker of any amount
of alcohol), regular exercise (yes or no), and other characteristics,
including history and any medication. The participants’ weights,
heights, and blood pressures were measured in a standardized
manner. The BMI was calculated as weight in kilograms divided by
height in meters squared. Systolic and diastolic blood pressure were
measured in a seated position with a mercury sphygmomanometer or
automatic manometer. Fresh fasting serum specimens were analyzed
for laboratory tests. Fasting blood glucose, serum cholesterol, liver
function tests, and serum bilirubin concentrations were measured by
automated biochemical profiling (Hitachi-7600 analyzer, Hitachi
Ltd). Bilirubin concentrations were collected in milligram per
deciliter units. Serum creatinine was measured by a kinetic rate Jaffe
method.
Measurement of Outcome
The outcome variables were incidence of stroke and its subtypes
(ischemic, hemorrhagic, and all stroke types) as recorded in hospital
admission discharge records from 1994 to 2007 (median follow-up
duration, 9.4 years). We ascertained these outcomes from health
insurance claim data from the National Health Insurance Corporation
and checked fatal cases from the national death certification data.22,23
Ischemic, hemorrhagic, and all stroke types were defined according
to the International Classification of Diseases 10th Revision codes:
ischemic stroke, I63-I639; hemorrhagic stroke, I60-I629; and all
stroke types, I60-I699. For those individuals with 1 event during
the follow-up period, we considered only the first event in our
statistical analyses. Morbidity was recorded according to the Inter-
national Classification of Diseases 10th Revision codes in a stan-
dardized manner.22–24 The accuracy rate of the International Classi-
fication of Diseases codes for cerebrovascular diseases in medical
insurance claims for men in Korea was reported as 83.0% in 2000.25
Statistical Analysis
We classified the concentrations of serum bilirubin into 4 levels: 0 to
10.2, 10.3 to 15.3, 15.4 to 22.1, and 22.2 to 34.2 mol/L (to convert
bilirubin from milligrams per deciliter to micromoles per liter,
multiply by 17.1). Type 2 diabetes was defined as participants with
self-reported diagnosis of type 2 diabetes or participants with fasting
blood glucose levels 126 mg/dL. Hypertension was defined as a
systolic blood pressure of at least 140 mm Hg, a diastolic blood
pressure of at least 90 mm Hg, or a self-reported diagnosis of
hypertension.
To examine the differences of baseline characteristics of the 4
levels of bilirubin, age-adjusted ANOVA and 2 test were used. The
incidence rates per 100 000 person-year were calculated. Partial
Pearson correlation coefficients were acquired to determine the
relationship between log-transformed bilirubin and other variables
with adjustment for age. Log-transformed bilirubin concentrations
were used to achieve normal distribution. Cox proportional hazards
models were used to estimate the risk of stroke incidence according
to serum bilirubin levels. Crude (model I), age-adjusted (model II),
and multivariable-adjusted (model III) analyses were performed with
consideration for multicollinearity. We adopted the multivariable
model used in the Framingham offspring study,7 in addition to the
GGT, a new risk factor for cardiovascular disease mortality.26
Finally, the hazard ratios (HR) in model III were adjusted for age,
smoking (nonsmoker, ex-smoker, current smoker), alcohol (yes or
no), exercise (yes or no), alanine transaminase, total cholesterol, type
2 diabetes, hypertension, and GGT. The HR and 95% CI were
calculated. All analyses were conducted using SAS statistical soft-
ware version 9.1 (SAS institute Inc) and performed separately for
men and women because frequency rates in the 4 bilirubin levels
were different between men and women (P0.0001 by 2 test). All
statistical tests were 2-sided, and statistical significance was deter-
mined as P0.05.
Results
MeanSD of bilirubin concentration was 15.15.6 mol/L
in men (n41 054) and 11.64.7 mol/L in women
(n37 670; P0.0001). During a 14-year follow-up, a total
of 1964 men and women were hospitalized for stroke. Among
all the stroke patients, the proportion of patients having
ischemic stroke were 63.1% for men and 57.1% for women,
respectively.
The mean age of study participants decreased as levels of
serum bilirubin in both men and women increased
(P0.0001). There was not an even distribution of general
characteristics among the 4 bilirubin levels which included
age, BMI, alanine transaminase, total cholesterol, and smok-
ing habit. GGT and hypertension in women, alcohol, exer-
cise, and type 2 diabetes in men were also associated with
bilirubin levels (Table 1). In age-adjusted partial correlation
analysis, aspartate aminotransferase, systolic blood pressure,
fasting blood glucose, triglyceride, high-density lipoprotein,
serum creatinine, and hemoglobin were also correlated with
log-transformed bilirubin concentrations (Table 2).
There was strong multicollinearity among aspartate ami-
notransferase, alanine transaminase, and GGT, and also
between total cholesterol and triglyceride. When we analyzed
with several alternate models with or without systolic blood
pressure, fasting blood glucose, GGT, BMI, creatinine, he-
moglobin, triglyceride, high-density lipoprotein, and choles-
terol/high-density lipoprotein ratio,19 there was no difference
in the final results showing the association between bilirubin
levels and stroke incidence (data not shown).
In Cox proportional hazard models, participants with
higher levels of bilirubin showed lower HR in men with
ischemic stroke before and after adjustment for age (model II)
or multiple (model III) confounding factors compared with
the lowest level of bilirubin (HR, 0.72; 95% CI, 0.58–0.90 in
level 3; HR, 0.66; 95% CI, 0.49–0.89 in level 4; P for
trend0.016). The risk for all stroke types also decreased as
bilirubin levels increased (HR, 0.81; 95% CI, 0.68–0.97 in
level 3; HR, 0.74; 95% CI, 0.58–0.94 in level 4; P for
trend0.0071). However, these associations were not seen in
hemorrhagic stroke or in women (Tables 3 and 4).
We also did the Cox proportional hazard analysis with
bilirubin as a continuous variable. For ischemic stroke, a
1 mol/L increment in bilirubin concentration was associated
with a 2% reduction of HR (HR, 0.98; 95% CI. 0.97–0.99;
P0.0138) and a 1-log bilirubin (mol/L) increment was
associated with a 23% reduction in HR (HR, 0.77; 95% CI.
0.63–0.94) in a multivariate-adjusted model for men. For all
stroke types, there was a 1% reduction of HR (HR, 0.99; 95%
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CI, 0.98–1.00; P0.0382) and a 15% reduction of HR (HR,
0.85; 95% CI, 0.72–0.99; P0.0358), respectively (data not
shown). Similar results were observed when we divided the
participants into quartiles (please see Table I, available online
at http://stroke.ahajournals.org). We grouped the bilirubin
concentrations into 5 levels using the design used in the
Framingham offspring study.7 The multivariable adjusted
HR, which compared ischemic stroke in the highest quintile
to that in the lowest quintile, showed a significant decrease in
men (HR, 0.71; 95% CI, 0.56–0.90), but the HR for all stroke
types was not significant (please see Table II).
In men, we saw a protective trend of bilirubin against a risk
of hemorrhagic stroke in an unadjusted model for the trend
test (P for trend0.0151), but it disappeared when we
adjusted for age and other confounding variables (Table 3).
In women, we found significant associations between
bilirubin and stroke in an unadjusted model for ischemic
stroke (HR, 0.71; 95% CI, 0.54–0.94 in level 3; P for
trend0.0046) and all stroke types (HR, 0.72; 95% CI,
0.58–0.89 in level 3; P for trend0.0024). In adjusted
models, there was no remaining significant relationship
between bilirubin and the various stroke types in women
(Table 4).
Discussion
Even after adjusting for age and other well-known risk
factors, the serum bilirubin level still was independently
associated with the incidence of ischemic and all stroke types
dose-dependently in men, but not in women. The result of our
study on stroke coincides with previous reports that bilirubin
is an independent inverse predictor for CVD.
In previous studies, a U-shape correlation between biliru-
bin and cardiovascular risk was described9,11 or suggested.7,19
In our report, we divided the bilirubin concentrations into 4
levels by a concentration range in contrast to previous studies
to provide information on these concentrations. However, we
performed alternate grouping to check this issue. Our analysis
using the same grouping as the Framingham offspring study7
showed decreased risk of ischemic stroke in higher biliru-
bin levels in men. However, there was no significant
Table 1. Baseline Characteristics of the Study Population According to the Bilirubin Levels
Bilirubin Levels (mol/L)
1 0–10.2 2 10.3–15.3 3 15.4–22.1 4 22.2–34.2 P
Men (n41 054) 5422 16 220 14 099 5313
Age, yr 48.610.5 48.110.3 46.910.0 45.69.8 0.0001
BMI, kg/m2 23.62.7 23.92.7 23.92.7 23.72.8 0.0001
ALT, IU/L 26.513.2 26.713.6 26.213.5 25.613.3 0.0001
GGT, IU/L 39.939.1 40.438.6 40.340.6 39.144.1 0.1823
Cholesterol, mg/dL 196.435.1 199.034.2 196.933.4 193.233.5 0.0001
Bilirubin, mol/L 7.61.3 12.01.4 17.41.9 25.73.5 0.0001
Log bilirubin, mol/L 2.00.2 2.50.1 2.90.1 3.20.1 0.0001
Current smoker 3392 (62.6) 8914 (55.0) 6649 (47.2) 2334 (43.9) 0.0001
Alcohol drinker 4505 (83.1) 13855 (85.4) 12293 (87.2) 4664 (87.8) 0.0001
Regular exercise 2490 (45.9) 6808 (42.0) 5969 (42.3) 2318 (43.6) 0.0001
Type 2 diabetes 425 (7.8) 1119 (6.9) 932 (6.6) 285 (5.4) 0.0001
Hypertension 1370 (25.3) 3990 (24.6) 3548 (25.2) 1275 (24.0) 0.2810
Women (n37 670) 13 543 16 172 6318 1637
Age, yr 48.710.2 47.710.1 46.29.9 45.39.8 0.0001
BMI, kg/m2 23.33.1 23.13.1 22.93.1 22.53.0 0.0001
ALT, IU/L 17.99.6 17.49.7 16.99.5 16.69.8 0.0001
GGT, IU/L 18.516.2 18.016.1 17.315.4 17.317.2 0.0001
Cholesterol, mg/dL 196.936.6 197.037.2 193.937.3 191.637.2 0.0001
Bilirubin, mol/L 7.41.4 11.61.3 17.11.8 25.43.3 0.0001
Log bilirubin, mol/L 2.00.2 2.50.1 2.80.1 3.20.1 0.0001
Current smoker 898 (6.6) 838 (5.2) 275 (4.4) 69 (4.2) 0.0001
Alcohol drinker 4939 (36.5) 6001 (37.1) 2391 (37.8) 617 (37.7) 0.2645
Regular exercise 7741 (57.2) 9008 (55.7) 3557 (56.3) 914 (55.8) 0.0879
Type 2 diabetes 512 (3.8) 641 (4.0) 240 (3.8) 71 (4.3) 0.6402
Hypertension 3118 (23.0) 3595 (22.2) 1342 (21.2) 324 (19.8) 0.0027
Data are shown as meanSD for continuous variables and N (percent) for categorical variables. For continuous variables,
age-adjusted ANOVA test was used.
ALT indicates alanine transaminase.
Type 2 diabetes: self-reported diagnosis or with fasting blood glucose 126 mg/dL; hypertension: self-reported diagnosis, or
systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg.
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association between bilirubin and the risk of all stroke
types in men. This result implies the possibility that the
U-shape was attributable to the lack of analysis for the
subtypes of CVD.
In our study, we presented each HR for ischemic, hemor-
rhagic, and all stroke types rather than total CVD, and found
some differences between the results from ischemic stroke
and the results from hemorrhagic stroke. A stronger associ-
ation of bilirubin with the risk of ischemic stroke than with
the risk of hemorrhagic stroke may support the antiathero-
genic property of bilirubin suggested in previous reports.19
Bilirubin has been shown to be a natural antioxidant.3,4 As an
antioxidant, bilirubin demonstrated antiatherogenic function
through inhibition of low-density lipoprotein oxidation27,28 or
through inhibition of vascular endothelial activation, which may
mediate the antiatherogenic properties of heme oxygenase-1.29
The antiatherogenic potential of bilirubin was also shown in
human studies. Carotid intima-media thickness, a predictor for
atherosclerosis, increased in healthy subjects with low bilirubin
levels not only in men17 but also in women.18
However, in longitudinal cohort studies, the association
between bilirubin and mortality12 or between bilirubin and
cardiovascular disease7 did not reach statistical significance
in women. The Framingham Offspring Cohort reported in-
verse associations between bilirubin and cardiovascular dis-
eases when they analyzed CVD not specific for coronary
heart disease or stroke in men but not in women among 4276
participants during a 22-year follow-up. The multivariate-
adjusted HR for risk of CVD for the higher bilirubin group
(14.53–17.94 mol/L) compared to the lowest group was
0.59 (95% CI, 0.39–0.89) in men,7 which is comparable with
our findings (HR, 0.72; 95% CI, 0.58–0.90) of 15.4 to
Table 2. Age-Adjusted Partial Correlation Coefficients Between
Log Bilirubin Concentration and Other Variables Measured
Men (n41 054) Women (n37 670)
Correlation
Coefficient P
Correlation
Coefficient P
Aspartate
aminotransferase
0.0238 0.0001 0.0372 0.0001
ALT 0.0374 0.0001 0.0160 0.0013
GGT 0.0075 0.1197 0.0097 0.0518
Systolic blood pressure 0.0361 0.0001 0.0157 0.0017
Diastolic blood
pressure
0.0162 0.0008 0.0001 0.9913
Fasting blood glucose 0.0132 0.0063 0.0176 0.0004
Total cholesterol 0.0227 0.0001 0.0136 0.0066
Triglyceride 0.0739 0.0001 0.0953 0.0001
High-density lipoprotein
cholesterol
0.0926 0.0001 0.0604 0.0001
Hemoglobin 0.1559 0.0001 0.1762 0.0001
BMI 0.0032 0.5066 0.0348 0.0001
Serum creatinine 0.0281 0.0001 0.0573 0.0001
Log-transformed bilirubin concentrations were used to achieve normal
distribution.
Table 3. HR and 95% CI for Ischemic, Hemorrhagic, and All Stroke Types According to Bilirubin Levels in
Men, 1994–2007 (n41 054)
Bilirubin levels (mol/L)
0–10.2 10.3–15.3 15.4–22.1 22.2–34.2 P
N (%) 5422 (13.2) 16 220 (39.5) 14 099 (34.3) 5313 (12.9)
Ischemic stroke
Cases 145 302 209 61
Incidence rate 311.4 216.8 171.7 131.9
Model I 1.00 0.70 (0.57–0.85) 0.55 (0.45–0.68) 0.42 (0.31–0.57) 0.0001
Model II 1.00 0.73 (0.60–0.89) 0.64 (0.52–0.79) 0.55 (0.41–0.75) 0.0001
Model III 1.00 0.80 (0.65–0.97) 0.72 (0.58–0.90) 0.66 (0.49–0.89) 0.0016
Hemorrhagic stroke
Cases 41 118 79 26
Incidence rate 87.4 84.3 64.6 56.1
Model I 1.00 0.97 (0.68–1.34) 0.74 (0.51–1.08) 0.64 (0.39–1.05) 0.0151
Model II 1.00 1.00 (0.70–1.42) 0.83 (0.60–1.21) 0.79 (0.48–1.29) 0.1558
Model III 1.00 1.05 (0.73–1.50) 0.87 (0.59–1.27) 0.80 (0.48–1.32) 0.1753
All stroke
Cases 207 476 349 105
Incidence rate 446.6 343.3 287.9 227.8
Model I 1.00 0.77 (0.63–0.91) 0.64 (0.54–0.77) 0.51 (0.40–0.64) 0.0001
Model II 1.00 0.80 (0.68–0.94) 0.74 (0.62–0.88) 0.65 (0.51–0.82) 0.0001
Model III 1.00 0.86 (0.73–1.01) 0.81 (0.68–0.97) 0.74 (0.58–0.94) 0.0071
Incidence ratecases/100 000 person-year; model I: unadjusted; model II: adjusted for age; model III: adjusted for age, smoking
(nonsmoker, ex-smoker, current smoker), alcohol (yes or no), exercise (yes or no), ALT, GGT, total cholesterol, type 2 diabetes, and
hypertension.
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22.1 mol/L for ischemic stroke. These differences in men
and women may be attributable to lifestyle factors, including
tobacco, alcohol, or diet. Postmenopausal women and men
accumulate higher levels of stored iron than young women,30
and high dietary intake of heme iron has been known to be
associated with increased coronary heart disease risk.31 We
cannot exclude a potential effect of iron load to the heme
oxygenase-1 and bilirubin pathway.29
Defining hyperbilirubinemic subgroup and excluding po-
tential liver disease patients was pointed as a key step to
clarify the inverse associations between bilirubin and stroke
in discussions from other published works.32 We modified the
exclusion criteria of the NHANES study: a report on active
liver diseases, 2-times higher than normal value of alanine
transaminase, bilirubin 34.2 mol/L, or albumin 3.5
mg/dL, and adjustment for alcohol intake.19 We also excluded
the potential Gilbert syndrome group because it has been
known that they had lower prevalence and incidence of
coronary heart diseases and had higher high-density lipopro-
tein and antioxidant levels.6 However, we could not find any
difference in the risk of stroke among the potential Gilbert
syndrome group, the potential hepatobiliary disease group,
and the main analysis group in our additional analysis. When
we calculated HR without excluding them (n95 220), the
results did not differ from that reported.
This study has several limitations. The representation of
our participants is limited and the variables of stroke prog-
nosis or dietary intake are lacking. We also cannot rule out
selection bias in our volunteers who may have had healthier
lifestyles. Bilirubin concentration was measured only once,
but we thought the possibility of confounders from biliary
disease might be minimal because we excluded subjects with
abnormal liver enzymes and with histories of hepatobiliary
diseases. The accuracy rate for cerebrovascular diseases in
medical insurance claims for men was reported previously,25
but there were limited data for women.
It was reported that among the stoke cases, 15% of the
cases were hemorrhagic stroke, 70% of the cases were
cerebral infarction, and 15% of the cases were transient
ischemic attack (TIA).33 We did not include TIA in the all
stroke types category because TIA patients are likely to be
missed from the admission record because of the mild,
transient symptom.
Our study has a few strengths. First, we analyzed a large
population with men and women. Second, we excluded
subjects with potential hepatobiliary diseases or Gilbert
syndrome. Third, the characteristics of participants were
homogenous because they were all urban middle class.
Finally, we clarified the specific risk for the subgroups of
stroke, including ischemic and hemorrhagic stroke.
Bilirubin assay is available in many laboratories and is not
expensive. The results in this large cohort study support the
potential role of bilirubin to predict stroke. Our findings
suggest that serum bilirubin might have some protective
function against stroke in men. Further studies are needed to
confirm the association of bilirubin with stroke. A larger
Table 4. HR and 95% CI for Ischemic, Hemorrhagic, and All Stroke Types According to Bilirubin Levels in
Women, 1994–2007 (n37 670)
Bilirubin Levels (mol/L)
0–10.2 10.3–15.3 15.4–22.1 22.2–34.2 P
N (%) 13 543 (36.0) 16 172 (42.9) 6318 (16.8) 1637 (4.4)
Ischemic stroke
Cases 194 195 67 16
Incidence rate 166.8 137.8 120.0 110.0
Model I 1.00 0.82 (0.67–1.00) 0.71 (0.54–0.94) 0.77 (0.39–1.08) 0.0046
Model II 1.00 0.91 (0.75–1.11) 0.93 (0.70–1.23) 0.94 (0.57–1.57) 0.5055
Model III 1.00 0.90 (0.74–1.10) 0.88 (0.67–1.17) 0.91 (0.55–1.52) 0.3253
Hemorrhagic stroke
Cases 75 99 28 7
Incidence rate 64.2 69.8 50.0 48.0
Model I 1.00 1.09 (0.80–1.47) 0.78 (0.50–1.12) 0.75 (0.34–1.62) 0.2782
Model II 1.00 1.17 (0.87–1.58) 0.93 (0.60–1.44) 0.97 (0.45–2.10) 0.9540
Model III 1.00 1.16 (0.86–1.56) 0.90 (0.58–1.34) 0.94 (0.43–2.03) 0.8158
All stroke
Cases 314 376 109 28
Incidence rate 270.9 266.8 195.9 192.9
Model I 1.00 0.98 (0.84–1.14) 0.72 (0.58–0.89) 0.70 (0.48–1.03) 0.0024
Model II 1.00 1.07 (0.92–1.25) 0.90 (0.72–1.12) 0.97 (0.66–1.43) 0.6072
Model III 1.00 1.07(0.92–1.24) 0.87 (0.70–1.09) 0.94 (0.64–1.38) 0.4193
Incidence ratecases/100 000 person-year; model I: unadjusted; model II: adjusted for age; model III: adjusted for age, smoking
(nonsmoker, ex-smoker, current smoker), alcohol (yes or no), exercise (yes or no), ALT, GGT, total cholesterol, type 2 diabetes, and
hypertension.
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sample size or longer follow-up time might have detected
significant findings in the risk of hemorrhagic stroke, as well
as in the risk of any type of stroke in women. Clarification of
the protective bilirubin cut-off level and intervention trials
may answer the question of the potential for bilirubin as a
therapeutic target for CVD.
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